Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00427180
Other study ID # SP-80-00-00-00-01-V01
Secondary ID SP-80-00-00-00-0
Status Active, not recruiting
Phase N/A
First received January 25, 2007
Last updated March 2, 2010
Start date December 2006
Est. completion date December 2010

Study information

Verified date March 2010
Source Intelligent Medical Implants GmbH
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical DevicesUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Switzerland: SwissmedicAustria: Federal Office for Safety in Health Care
Study type Interventional

Clinical Trial Summary

Investigate whether blind subjects that fulfil the patient criteria provided with a Retinal Implant are able to differentiate between simple patterns like horizontal bar, vertical bar and cross.


Description:

The Retinal Implant System consists of three main components, the Retinal Stimulator, which is the component actually implanted into the eye, the visual interface, and the Pocket Processor The Retinal Stimulator will be implanted into the eye of a blind subject during a surgical operation. However, the external components are activated only during the test sessions under the control of the investigator team. In a first step of the investigation a software controlled system on a PC which is connected to the Pocket Processor via Ethernet interface, will generate the defined stimulation patterns (bars, crosses, cubes). During the test session, the blind subject is exposed to a series of these stimulation patterns and he / she has to describe the visual perceptions. Based on his descriptions and in an interactive way, the stimulation signal is subsequently be modulated by changing parameters like amplitude, duration of impulse, polarity, number of repetitions or pulse frequency on the PC.

In a second step the visual interface is equipped with a camera which presents realtime images to the subject. Data obtained from the investigation with computer generated patterns in the first step are used in the second step to improve the fitting software for the use in the camera supported system.

Finally the system should enable the subject to recognize simple images supported from the camera.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date December 2010
Est. primary completion date November 2010
Accepts healthy volunteers No
Gender Both
Age group 30 Years to 79 Years
Eligibility Inclusion Criteria

- Age between 30 and 79 years at the date of enrollment

- Normal hearing and linguistic understanding (with hearing aids if - necessary and in the language of the hospital or in English)

- Ability to understand the study and procedures involved

- Willingness to participate and comply with follow-up procedures

- Good general health based on investigator's opinion

- Ability to undergo surgery using general anaesthesia

- Signed informed consent

- RP, choroideremia, or rod cone dystrophy

- Visual field less than 40 ° (if measurable)

- Visual acuity not better than (1/50), (logMAR=1.7)

- Visual function stable for a duration of at least one year (according to subject statement)

- Normal eye pressure (9-21 mmHg)

- Bulbus length (AP) between 21 and 25 mm

Exclusion Criteria

- Allergic response to multiple antibiotics

- Known allergies to materials of the implant

- Known carrier of multi-resistant organisms

- Pregnancy or lactating

- History of epileptic seizures

- Having active implantable devices (or need within the next 3 years)

- Patients with cancer or patients received cancer therapy within the last 2 years

- Currently undergoing psychiatric treatment without expert opinion approving participation on the study

- Patients having insufficient mental capacity

- Neurological diseases, in particular those affecting nerve conduction velocities

- Patients currently taking medications affecting brain function

- Immunosuppressive subjects

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Device:
Retinal Implant System (IRIS)
AIMD - Active Implantable Medical Device designed for artificial electrical neural stimulation of photoreceptor degenerated retina

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Intelligent Medical Implants GmbH

References & Publications (1)

Hornig R, Laube T, Walter P, Velikay-Parel M, Bornfeld N, Feucht M, Akguel H, Rössler G, Alteheld N, Lütke Notarp D, Wyatt J, Richard G. A method and technical equipment for an acute human trial to evaluate retinal implant technology. J Neural Eng. 2005 Mar;2(1):S129-34. Epub 2005 Feb 22. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Investigate whether blind subjects that fulfill the patient criteria provided with a Retinal Implant are able to differentiate between simple patterns like horizontal bar, vertical bar and cross. 18 months No
Secondary Secondary goals of this study phase are: Further evaluation of stimulation parameters, Light localization with use of camera, Safety verification of stimulation parameters 18 months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT01432847 - Cell Collection to Study Eye Diseases
Completed NCT04983914 - Retrospective NIS to Evaluate the Patient Benefit of TES
Recruiting NCT03845218 - Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
Completed NCT00231010 - Molecular Genetics of Retinal Degenerations
Active, not recruiting NCT04611503 - PDE6A Gene Therapy for Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT02909985 - Visual Activity Evoked by Infrared in Humans After Dark Adaptation N/A
Recruiting NCT01914913 - Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT01949623 - Biomarkers In Retinitis Pigmentosa (BIRP) N/A
Completed NCT01835002 - Transcorneal Electrical Stimulation - Multicenter Safety Study N/A
Completed NCT00407602 - Argus® II Retinal Stimulation System Feasibility Protocol N/A
Completed NCT00515814 - Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors N/A
Completed NCT00100230 - DHA and X-Linked Retinitis Pigmentosa Phase 2
Active, not recruiting NCT00378742 - Repository for Inherited Eye Diseases
Terminated NCT05085964 - An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa Phase 2
Recruiting NCT05805007 - Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa Early Phase 1
Recruiting NCT06291935 - Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene Phase 1
Recruiting NCT05909488 - Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II Phase 2/Phase 3
Recruiting NCT03078309 - The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients Early Phase 1
Completed NCT04238858 - Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa N/A
Active, not recruiting NCT01680510 - The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil Phase 1/Phase 2